Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076063 · ClinicalTrials.gov registry record · Phase 1
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
- 11
- Study locations
NCT00076063: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00076063 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 174 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (61% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00076063, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it. The canarypox virus cannot cause disease in people. LIPO-5 is a mixture of five man-made proteins similar to proteins found in HIV. These vaccines are not produced from live HIV or from infected cells and do not contain the virus. It is not possible to become infected with HIV from these vaccines.
Conditions Studied
Interventions
- BIOLOGICAL ALVAC-HIV (vCP1452)
- BIOLOGICAL LIPO-5
Study Locations (11)
Maryland
- Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore - Baltimore
- Project Brave HIV Vaccine CRS - Baltimore
Massachusetts
- Brigham and Women's Hosp. CRS - Boston
- Fenway Community Health Clinical Research Site (FCHCRS) - Boston
New York
- Univ. of Rochester HVTN CRS - Rochester
- NY Blood Ctr./Bronx CRS - The Bronx
Alabama
- Alabama Vaccine CRS - Birmingham
Missouri
- Saint Louis Univ. School of Medicine, HVTU - St Louis
Rhode Island
- Miriam Hospital's HVTU - Providence
Tennessee
- Vanderbilt Vaccine CRS - Nashville
Washington
- FHCRC/UW Vaccine CRS - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
What the finished NCT00076063 record still lists
NCT00076063 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (61% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which ALVAC-HIV (vCP1452) is the first listed.
NCT00076063 lists 11 locations in 8 states (Maryland, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT00076063 about?
NCT00076063 is a clinical study titled "A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines". This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it. The canarypox virus cannot cause disease in people. LIPO-5 is a mixture of...
What is the current status of trial NCT00076063?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2004-03. Estimated completion is 2007-03.
What conditions does trial NCT00076063 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00076063?
The interventions under investigation include: ALVAC-HIV (vCP1452) (BIOLOGICAL), LIPO-5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00076063?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076063 being conducted?
This trial has 11 study locations across Alabama, Maryland, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00076063's enrollment target sits among peer trials
174 194th of 542 higher than 349 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia